BridgeBio Pharma And Bayer Announce European Licensing Agreement For Acoramidis In ATTR-CM, BridgeBio To Receive $310M Plus Royalties
Portfolio Pulse from Benzinga Newsdesk
BridgeBio Pharma and Bayer have entered into a licensing agreement for acoramidis in Europe, targeting ATTR-CM. BridgeBio will receive up to $310 million in payments plus royalties. Their New Drug Application for acoramidis has been accepted by the FDA, with a PDUFA date set for November 29, 2024, and the EMA has accepted the Marketing Authorization Application, expecting approval in 2025.
March 04, 2024 | 7:34 am
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Bayer secures exclusive rights to commercialize acoramidis in Europe, leveraging its expertise in cardiovascular medicine to potentially enhance its product portfolio.
Bayer's acquisition of exclusive rights to commercialize acoramidis in Europe represents a strategic move to bolster its cardiovascular medicine portfolio. The partnership with BridgeBio, which brings a promising treatment for ATTR-CM closer to market, could significantly impact Bayer's market position and revenue in the cardiovascular domain.
CONFIDENCE 85
IMPORTANCE 75
RELEVANCE 80
POSITIVE IMPACT
BridgeBio Pharma stands to gain significantly from the licensing agreement with Bayer, receiving up to $310 million plus royalties for acoramidis in Europe.
The agreement with Bayer not only provides BridgeBio with substantial upfront and milestone payments but also ties the company to a tiered royalty structure that could significantly enhance its revenue stream, especially given the blockbuster potential of acoramidis. The acceptance of their New Drug Application by the FDA and the Marketing Authorization Application by the EMA further solidifies the drug's potential success.
CONFIDENCE 90
IMPORTANCE 85
RELEVANCE 90